WILMINGTON, Delaware, Jan. 10, 2025 (GLOBE NEWSWIRE) — Aimfinity Investment Corp. I (NASDAQ: AIMAU) (the “Company”), a blank check company incorporated as an exempt company in the Cayman Islands, announced today that it has held an extraordinary general meeting of shareholders (the “Extraordinary General Meeting “) is the end of In place of the Annual General Meeting to be held on January 9, 2025, which was earlier postponed to December 30, 2024.

At the Extraordinary General Meeting, the Company’s shareholders, by special resolution, approved the amendment of the Company’s Third Amended and Restated Memorandum and Articles of Association (the “Charter”) to provide for the Company’s initial incorporation by January 28, 2025. Business can be allowed to complete. may elect to extend the period up to nine times to effect the combination and initial business combination, each additional one month in the Company’s trust account (the “Trust Account”) for each one month extension for each public share held; by depositing $0.05, for a total period of nine months beginning October 28, 2025 (each such deposit, a “Monthly Extended Payment”).

In addition, the shareholders, through ordinary resolutions, also re-elected Mr. Kevin D. Wasley, an independent director and chairman of the audit committee for a three-year term, and Malone Bailey, LLP as the company itself. Confirmed appointment of Mukhtar. Registered public accounting firm for the fiscal years ending December 31, 2023 and 2024.

Subject to shareholder approval, the Company may extend on a monthly basis from January 28, 2025 to October 28, 2025, or such earlier date as may be requested by the Company’s sponsor, Amfinity Investments LLC (the “Sponsor”). may have gone , and has been authorized by its board to complete a business collection account by depositing the monthly extension payment for each month into the trust account.

Aimfinity Investment Corp. About I

Aimfinity Investment Corp. I is a blank check company incorporated as a Cayman Islands exempt company for the purpose of effecting a merger, exchange of shares, acquisition of assets, purchase of shares, reorganization or similar business combination with one or more businesses or entities. has been added. The Company has not selected any Business Combination Target, nor has any person on its behalf, directly or indirectly, any substantial relationship with any Business Combination Target in connection with the initial Business Combination. The conversation has started. Although the Company will not be limited to a particular industry or geographic region in identifying and acquiring a target company, it will not complete its initial business combination with a target that is headquartered in China (including Hong Kong and Macau). The majority of its business in China (including Hong Kong and Macau).

Additional information and where to find it.

As previously disclosed, on October 13, 2023, the Company entered into this Specific Agreement and Plan of Merger (as amended from time to time, supplement or as may be otherwise amended, the “Merger Agreement”), by and among the Company, Doctor Inc., a Delaware corporation (the “Company”), Aimfinity Investment Merger Sub I, a Cayman Islands exempt company and a wholly owned subsidiary of Parent (the “Buyer”), and Aimfinity Investment Merger Sub II, Inc., a A Delaware corporation and a wholly-owned subsidiary of Buyer (the “Subsidiary”), pursuant to which the Company is proposing to enter. Involved in business combinations with Docter including a reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered regarding the proposed business combination and is not intended to inform any investor. Not to form the basis of any other decision in connection with a business decision or business combination. AIMA’s stockholders and other interested persons are advised to read the proxy statement/prospectus and the amendments thereto and the proposed proxy statement/prospectus when available. Read the other documents filed in connection with the business combination, as these materials will contain important information about AIMA, the buyer or practitioner, and the proposed business combination. When available, the proxy statement/prospectus and other related materials for the proposed business combination to AIMA’s stockholders for voting on the proposed business combination. The records to be established will be sent according to the date. Also obtain copies of such stockholders’ proxy statements/prospectus and other documents filed with the Securities and Exchange Commission (“SEC”). will be available, without charge, once available, at the SEC’s website at www.sec.gov, or at AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801. By sending an application.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about pending transactions described herein, and the views and expectations of the parties, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, benefits of the proposed transaction, integration plans, anticipated synergies and revenue opportunities, Anticipated future financial and operating. performance and results, including growth projections, anticipated management and governance of the combined company, and anticipated timing of the transaction. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, due to Actual results may differ materially. Which is implied or implied.

Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of consummation of the pending business combination, including the risk that one or more of the transactions may close; The transaction cannot be closed due to conditions of Failure to satisfy or excuse, such as failure to obtain regulatory approvals, on a timely basis or otherwise, or that a governmental entity prohibits, delays or refuses to grant approvals for the consummation of the Transaction or such approvals; Require certain conditions, limitations or restrictions in connection; (ii) risks related to AIMA and Doctor’s ability to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstance that may give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change in AIMA’s or Doctor’s financial position, performance, operations or prospects; (v) risks related to management disruption of ongoing business operations due to the proposed transaction; (vi) the risk that any announcements regarding the proposed transaction may adversely affect the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement may adversely affect Doctor’s ability to retain customers and retain and hire key personnel and maintain relationships with its suppliers and customers and its operating results and business; But generally can have a negative effect. (viii): risks related to the medical device industry, including but not limited to changes in government regulation and enforcement, market competition, competing products and pricing activity; and (ix) risks related to the combined company’s ability to expand its products and services, execute its business strategy, expand its customer base and maintain strong relationships with its business partners.

A further list and description of risks and uncertainties can be found in AIMA’s prospectus filed on April 26, 2022 in connection with AIMA’s initial public offering, AIMA on Form 10-K for the fiscal year ended December 31, 2022. Annual Report, was filed. on April 17, 2023, and in the registration statement/proxy statement filed by AIMA and/or its affiliates with the SEC in connection with the proposed transaction, and other documents that the parties may file or furnish with the SEC; Which you are encouraged to read. If one or more of these risks or uncertainties materialize, or underlying assumptions prove incorrect, actual results could differ materially from those indicated or anticipated. Statements are expected. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date they are made, and Aimfinity, Docter, and their subsidiaries undertake no obligation to update forward-looking statements to reflect events after the date. or may reflect circumstances, except as required by law or applicable regulation.

No offer or solicitation.

This press release is not a proxy statement or a solicitation of proxy, consent or permission with respect to any securities or in connection with any potential transaction and is not an offer to sell or a solicitation of an offer to buy any securities of AIMA. Purchaser or Doctor, nor the sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities will be made except by means of a prospectus that meets the requirements of the Securities Act.

Participants in the plea

AIMA, Dr., and their respective directors, executive officers, other members of management, and employees may, under SEC rules, be deemed participants in the solicitation of proxies by AIMA’s shareholders in connection with the proposed transaction. AIMA’s solicitation of shareholders in connection with the proposed business combination requires information about persons required by the SEC rules to be included in the proxy statement/prospectus on Form F-4 to be filed with the SEC.

Contact Information:

Aimfinity Investment Corp. I

I Fa Chang
Chief Executive Officer
221 W 9th St, PMB 235
Wilmington, Delaware 19801
[email protected]